All AbMole products are for research use only, cannot be used for human consumption.
HMN-214 (IVX-214, HMN214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. HMN-176 is an active metabolite of HMN-214 (IVX-214, HMN214). HMN-214 (IVX-214, HMN214) is an oral stilbene derivative. HMN-176 interferes with PLK1, but does not appear to directly inhibit PLK1. Instead, it alters its spatial distribution, resulting in cell cycle arrest at the G2–M phase, with destruction of the spindle polar bodies followed by DNA fragmentation. In human tumor xenografts, there was a broad spectrum of antitumor activity. The antitumor activity of HMN-214 (IVX-214, HMN214) was equal or superior to that of clinically available agents, including cisplatin, doxorubicin, vincristine, and tegafur-uracil.
| Cell Experiment | |
|---|---|
| Cell lines | HeLa, PC-3, DU-145, MIAPaCa-2, U937, MCF-7, A549, and WiDr cells |
| Preparation method | Seeding cells into a 96-well microplate at a density of 3 × 103–1 × 104 cells/well. Adding dilutions of HMN-214 or HMN-176 the next day and incubating the plate for 72 hours. Using the MTT assay to measure cells and then obtaining IC50 values . |
| Concentrations | 0–10 μM, dissolved in DMSO |
| Incubation time | 72 hours |
| Animal Experiment | |
|---|---|
| Animal models | Male BALB/c nude mice bearing xenografts of PC-3, A549, and WiDr cells |
| Formulation | Dissolved in 0.5% methylcellulose |
| Dosages | 10 mg/kg–20 mg/kg |
| Administration | Oral gavage on a QD ?28 schedule |
| Molecular Weight | 424.47 |
| Formula | C22H20N2O5S |
| CAS Number | 173529-46-9 |
| Solubility (25°C) | DMSO 10 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PLK Products |
|---|
| BI 2536
BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. |
| BI 6727
BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk1) with an IC50 of 0 .87 nM. |
| GSK461364
GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. |
| Rigosertib sodium
Rigosertib sodium is a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K). |
| GW843682X
GW 843682X is a PLK inhibitor for PLK1 and PLK3 with IC50 of 2.2 nM and 9.1 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
